Covalon Technologies Ltd. (OTCMKTS:CVALF) Short Interest Update

Covalon Technologies Ltd. (OTCMKTS:CVALF) was the recipient of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 100 shares, a decline of 92.3% from the December 31st total of 1,300 shares. Based on an average daily volume of 20,700 shares, the short-interest ratio is currently 0.0 days.

Covalon Technologies Stock Down 0.5 %

Shares of Covalon Technologies stock traded down $0.01 on Tuesday, hitting $2.13. The stock had a trading volume of 7,847 shares, compared to its average volume of 31,644. The stock has a market cap of $58.36 million, a price-to-earnings ratio of 30.43 and a beta of -0.27. The business’s 50 day moving average is $2.40 and its two-hundred day moving average is $2.25. Covalon Technologies has a twelve month low of $0.74 and a twelve month high of $3.08.

Covalon Technologies (OTCMKTS:CVALF) last announced its earnings results on Tuesday, January 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Covalon Technologies had a net margin of 8.58% and a return on equity of 12.33%.

Covalon Technologies Company Profile

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.